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The ageing process often leads to the development of numerous 
comorbidities which, consequently, are treated resorting to 
polypharmacy. The sharp increase in ageing index witnessed in 
Portugal for the past decade is a cause of major concern. In 
various countries, new pharmacist services have been emerging 
to tackle this problem, namely medication review. However, in 
Portugal, this service is not routinely provided, nor in the 
outpatient setting, neither in nursing homes. Therefore, this study 
aimed to analyse the quality of therapy in elderly nursing homes 
residents, by determining the prevalence of drug-related 
problems (DRP), and to conclude if there are missed 
opportunities for pharmacists.
Introduction
The application of explicit criteria in an elderly sample enabled the identification of a considerable number of PIMs. The most
commonly detected drugs as PIMs can lead to falls and fractures and nearly half of the sample with PIMs were indeed patients with
history of fractures. It would be interesting to evaluate if these have occurred in the following year. Applying implicit criteria also
revealed vast opportunities to improve safety and effectiveness of medicines, suggesting there are opportunities for pharmacists’
intervention in nursing homes. For these to attain maximum benefit, additional efforts must be put on multiprofessional collaboration
to diminish the absence of feedback to reports.
Conclusions
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Methods
Ethical approval
Invitation of 4 nursing homes (n=224)
Elegibility criteria: aged ≥65 and using ≥5 medicines
Cross-sectional study with clinical and therapeutic data 
collected from patient records 
Medication review using explicit and implicit criteria(1-4)
Detection of DRP (n=126), Potentially Inappropriate 
Medicines (PIMs) (n=161) and Potential Prescribing 
Omissions (n=126) 
Detected problems prioritized and reported to physicians, 
suggesting therapy changes 
Data analysis (Uni and bivariate statistics in IBM SPSS 21.0). 
CI 95%
.
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Flowchart 1: Pharmacist intervention and acceptance rate
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Figure 1: Prevalence of PIMs and PPOs
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